Cardiotoxicity of immune checkpoint inhibitors
Citations
1,032 citations
824 citations
Cites background from "Cardiotoxicity of immune checkpoint..."
...CTLA‐4 would compete with CD28 in binding to the CD80 and/or CD86 expressed on the DCs that results in a reduced inducible activity of DCs on CD8+ T cells with the subsequent suppression of these cells (Nejad et al., 2016; Varricchi et al., 2017; Figure 1)....
[...]
341 citations
218 citations
191 citations
References
13,081 citations
"Cardiotoxicity of immune checkpoint..." refers background in this paper
...107–109 IRAEs associated with the use of ipilimumab were already evident in phase I studies, but now their incidence and severity are well-recognised.(66) 110 IRAEs are common, usually reversible and not severe in most patients....
[...]
...In fact, combined anti-CTLA-4 and antiPD-1 blockade further enhances antitumour activity and patient survival.(66) 83 89 90 In addition, combination of four different types of immunotherapies eradicated several experimental tumours viewed as intractable....
[...]
10,674 citations
"Cardiotoxicity of immune checkpoint..." refers background in this paper
...The incidence of IRAEs seems to be lower with anti-PD-1 therapy than with ipilimumab.(9) 66 In general, IRAEs caused by ICIs resemble the autoimmune manifestations observed in PD-1-deficient mice....
[...]
10,602 citations
7,474 citations
6,869 citations